Can-Fite Validates Piclidenoson’s Canine Osteoarthritis Potential in Peer-Reviewed Study
Event summary
- Can-Fite’s Piclidenoson showed statistically significant improvement in mobility and pain assessments in dogs with osteoarthritis, per a study published in Frontiers in Veterinary Science on May 18, 2026.
- The study demonstrated significant reductions in LOAD scores, pain scores, and veterinarian-assessed lameness with no serious adverse events.
- Vetbiolix is conducting an advanced Phase 2 clinical study of Piclidenoson for canine osteoarthritis under a licensing agreement potentially worth up to $325 million.
The big picture
Can-Fite’s validation of Piclidenoson in canine osteoarthritis underscores the growing intersection of human and veterinary biotech markets. The multi-billion-dollar canine osteoarthritis market lacks effective oral therapies, making Piclidenoson a strategic asset for Vetbiolix. The partnership’s success could set a precedent for cross-industry drug repurposing.
What we're watching
- Commercial Viability
- Whether Piclidenoson can secure regulatory approval and market adoption as a novel oral therapy for canine osteoarthritis.
- Pipeline Progress
- The pace at which Vetbiolix advances Piclidenoson through Phase 2 and into potential Phase 3 trials.
- Revenue Potential
- How the $325 million licensing agreement with Vetbiolix will translate into milestone and royalty payments for Can-Fite.
Related topics